RALEIGH, N.C., March 10, 2016 /PRNewswire/ -- BioDelivery Sciences International, Inc. (NASDAQ: BDSI) reported financial results for the fourth quarter and full-year ended December 31, 2015, and reviewed its most significant recent accomplishments and upcoming milestones.
Net revenue for BUNAVAIL® (buprenorphine and naloxone) buccal film in the fourth quarter increased 29% to $1.5 million compared to the third quarter of 2015. BUNAVAIL net revenue for the 12-months ended December 31, 2015, was $4.2 million. BREAKYL® (brand name for ONSOLIS in the E.U.) revenue for the 12 month period was $1.4 million. BDSI net revenue for the 12-months ended December 31, 2015, was $48.2 million, compared to $38.9 million in the same period of 2014. This revenue increase was largely driven by the milestone payment received from Endo Pharmaceuticals upon the U.S. Food and Drug Administration (FDA) approval of BELBUCA (buprenorphine) buccal film, which generated $50 million in payments. Thirty ($30) million was attributed to the actual regulatory approval and was earned immediately while the additional $20 million was attributed to the extension of patent protection until 2027 from a patent granted in 2012 and payable on the FDA approval of BELBUCA. The latter aspect of the payment will be recognized over the patent extension period.
“We are pleased with our accomplishments in 2015, including the continued growth of BUNAVAIL prescriptions, and the approval of BELBUCA, our third FDA approved product, and the recently announced commercial launch in the United States,” said Dr. Mark A. Sirgo, President and Chief Executive Officer. “Looking ahead in 2016, we expect enhancements to our sales team, our recent agreement with Tennessee Medicaid, further commercial payer plan penetration and access, a pilot direct to consumer program, and certain government-driven initiatives, including the patient cap lift, to improve the growth trajectory of BUNAVAIL prescriptions. At the same time we will continue to explore strategic opportunities to maximize the value of that asset as well as our overall commercial infrastructure. In addition, we look forward to a strong BELBUCA launch from our partner Endo Pharmaceuticals and the continued advancement of our pipeline. With nearly $84 million in cash at the end of 2015, we continue to believe that BDSI has sufficient capital to support our current operating plan through approximately mid-2017.”
Financial Highlights
Fourth Quarter 2015 Financial Results Overview
- Net revenue for the fourth quarter ended December 31, 2015, was $32.2 million, nearly all attributable to the $50 million BELBUCA-related FDA approval payment of which $30 million was recognized as revenue immediately. The remaining $20 million will be recognized as revenue over the patent extension period. Revenue for the corresponding period for 2014 was $2.5 million, primarily related to BREAKYL. BUNAVAIL revenue for the fourth quarter was $1.5 million, an increase of 29% over third quarter.
- Total operating expenses for the fourth quarter ended December 31, 2015, were $18.6 million, compared to $17.6 million in the corresponding period of 2014.
- Net income for the fourth quarter ended December 31, 2015, was $10.2 million, or $0.19 per diluted share, compared to a net loss of $17.6 million, or ($0.36) per diluted share, in the corresponding period of 2014.
12-Months Ended December 31, 2015 Financial Results Overview
- Net revenue for the twelve months ended December 31, 2015, was $48.2 million, compared to $38.9 million in the corresponding period of 2014.
- Total operating expenses for the twelve-month period ended December 31, 2015, were $75.3 million, compared to $72.7 million the same period of 2014.
- Net loss for the 12-months ended December 31, 2015, was $37.7 million, or ($0.72) per diluted share, compared to $54.2 million, or ($1.12) per diluted share, in the corresponding period of 2014.
- As of December 31, 2015, BDSI had $83.6 million in cash and cash equivalents, as compared to $70.5 million as of December 31, 2014.
Corporate Update and Recent Accomplishments
BUNAVAIL (buprenorphine and naloxone) buccal film (CIII)
- BUNAVAIL prescriptions continued to grow, with a 66% increase from the third to fourth quarter of 2015. Since launch, over 75,000 prescriptions have been dispensed for BUNAVAIL.
- BUNAVAIL prescriber base expanded to nearly 2,549 physicians, with 447 unique prescribers added during the fourth quarter.
- Exclusive preferred formulary status for BUNAVAIL with Tennessee Medicaid was a key growth driver and added nearly 300 new BUNAVAIL prescribers in the state of Tennessee and over 7800 Medicaid prescriptions in the fourth quarter. BUNAVAIL prescription volume in Tennessee increased over 200% from the third quarter in the non-Medicaid segment (ie, commercial insurance and cash) as the Tennessee Medicaid formulary addition resulted in expanded BUNAVAIL use among other payer types.
- Market access improved through 2015 with coverage now in approximately 180 million commercial lives and Medicaid coverage expanded to 26 states.
BELBUCA (buprenorphine) buccal film (CIII)
- FDA approval for BELBUCA was received on October 23, 2015 resulting in a $50 million NDA approval milestone payment received from Endo; BDSI is now eligible for a mid to upper-teen royalty on future U.S. net sales of BELBUCA and up to $55 million in potential sales milestones.
- Launched commercially in the U.S. on February 22, 2016; Commercial partner, Endo Pharmaceuticals, currently projects sales of BELBUCA to be >$250 million in 2019
Clonidine Topical Gel Painful Diabetic Neuropathy
- Initiated multi-center, randomized, double-blind, placebo-controlled study, in fourth quarter of 2015. Study design incorporates significant learnings from two previously conducted studies where primary endpoints were not met and involves tightened and additional inclusion criteria.
- Expect last patient to complete the study before the end of 2016; data available in the first quarter of 2017.
Buprenorphine 30 Day Injection Pain & Opioid Dependence
- Pre-IND meeting with the FDA held in fourth quarter 2015.
- BDSI will conduct one additional preclinical study to characterize the time for elimination of the formulation polymers at the injection site.
- IND submission targeted for the third quarter of this year.
- Anticipate initiating first in man study in the fourth quarter of 2016, with results expected by end of year.
Key Anticipated 2016 Milestones
- Results of a pilot direct to patient advertising program for BUNAVAIL anticipated in early third quarter, with national expansion, if successful.
- FDA approval of induction claim for BUNAVAIL anticipated in third quarter.
- Last patient completes Clonidine Topical Gel Phase IIB study by year-end; data expected in the first quarter of 2017.
- IND filing of Buprenorphine 30 Day Injection for the treatment of opioid dependence and chronic pain anticipated in third quarter 2016; single dose pharmacokinetic study results anticipated by year-end.
Conference Call & Webcast
Thursday, March 10th @ 5pm Eastern Time
Toll Free: 888-572-7025
International: 719-325-2323
Passcode: 6142703
Webcast: http://public.viavid.com/index.php?id=118491
Replays, available through March 24, 2016
Toll-Free: 877-870-5176
International: 858-384-5517
Conference ID: 6142703
About BioDelivery Sciences International
BioDelivery Sciences International, Inc. (NASDAQ:BDSI) is a specialty pharmaceutical company with a focus in the areas of pain management and addiction medicine. BDSI is utilizing its novel and proprietary BioErodible MucoAdhesive (BEMA®) technology and other drug delivery technologies to develop and commercialize, either on its own or in partnership with third parties, new applications of proven therapies aimed at addressing important unmet medical needs.
BDSI’s development strategy focuses on utilization of the FDA’s 505(b)(2) approval process. This regulatory pathway creates the potential for more timely and efficient approval of new formulations of previously approved therapeutics.
BDSI’s particular area of focus is the development and commercialization of products in the areas of pain management and addiction. These are areas where BDSI believes its drug delivery technologies and products can best be applied to address critical unmet medical needs.
To read full press release, please click here.
